Boston Scientific Corp.

The U.S. Food and Drug Administration has issued a recall of Boston Scientific’s Obsidio conformable embolic medical device after an investigation found using the product for lower gastrointestinal bleeding embolization can result in a high risk of bowel ischemia, otherwise known as reduced or restricted blood flow.

The primary use of the funds will be used to fund Boston Scientific’s purchase of Axonics, Inc., a $3.7-billion transaction the company announced in January. 

Marlborough medical technology firm Boston Scientific has received approval from the U.S. Food and Drug Administration for its WaveWriter Alpha spinal cord stimulator device to be used to treat low back and leg pain deriving from a condition referred to as non-surgical back pain. 

The situation in Central Massachusetts, where 15.6% of named executive officers are female, largely mirrors the Massachusetts rate of 16.1% determined in a statewide census.

Marlborough medical device manufacturer Boston Scientific has reached agreement to purchase Axonics Inc., a company based in California specializing in devices used to treat urinary and bowel dysfunction.

Marlborough medical technology firm Boston Scientific has initiated a new clinical trial to study a treatment of persistent atrial fibrillation, an irregular rapid heart rhythm.

Worcester-based Hanover Insurance, Marlborough-based Boston Scientific, and Milford-based Waters Corp. have been named to the Human Rights Campaign Foundation’s Equality 100 Award list.

Marlborough medical device and technology firm Boston Scientific has completed its acquisition of a Minnesota-based medical company and its chronic low back pain treatment technology.

Boston Scientific, a Marlborough-based biomedical life sciences firm, is using electronic health records from 80 million U.S. patients to inform a new study into pulmonary embolism.

CVS Health, headquartered in Woonsocket, Rhode Island, has named Boston Scientific Chairman and CEO Michael Mahoney to its board of directors, effective November 1.